Earnings Results Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is scheduled to report its Q2 earnings results on July 30, 2026 after market close. Analysts expect the Healthcare…
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is scheduled to report its Q2 earnings results on July 30, 2026 after market close.
Analysts expect the Healthcare company to report earnings per share of $10.34, above the $0.00 reported in the same quarter last year. Revenue is expected to come in at $3.8B, up from a year ago.
The stock currently trades at $696.62 with a market capitalization of $77.2B.
Ahead of Regeneron Pharmaceuticals, Inc.'s earnings report, investors are watching several key metrics beyond the headline EPS number. Revenue growth, margin trends, and forward guidance will likely carry more weight than a single quarter's earnings figure in determining the stock's direction after the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Regeneron Pharmaceuticals, Inc. should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.
| Quarter | EPS Actual | EPS Est. | Surprise |
|---|---|---|---|
| Q1 (Apr 2026) | $9.47 | $8.38 | +13.0% |
| Q4 (Jan 2026) | $11.44 | $9.69 | +18.1% |
| Q3 (Sep 2025) | $11.83 | $9.78 | +21.0% |
| Q2 (Jun 2025) | $12.89 | $8.61 | +49.8% |
Related Tools: Earnings Calendar | View REGN Stock Page
Check the latest earnings dates on our REGN earnings page or the Earnings Calendar.
See the full Q2 results including EPS actual vs estimate on our REGN earnings page.
Current market data
NASDAQ · REGN
$794.19
Down: -$13.52 · -1.67%
Live quote updated
Keep reading
price ·
analyst ·
price ·
institutional ·
